Caris Life Sciences Inc Dossier - Source-backed chat

Caris Life Sciences Inc

CAINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $28.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $8B

Enterprise Value $7.6B

Shares Outstanding 282.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Caris Life Sciences (NASDAQ: CAI) represents a compelling investment opportunity in the precision oncology and AI TechBio space. Following its successful IPO in June 2025, the company has demonstrated exceptional top-line growth, with FY 2025 revenue surging 97% to $812 million and Q1 2026 revenue growing 79% to $216.2 million. Caris is successfully transitioning from a high-growth, capital-intensive business to a self-sustaining model, achieving positive Adjusted EBITDA of $137.7 million in FY 2025 and positive free cash flow. The company's massive clinico-genomic database of over one million profiled cases serves as a powerful competitive moat, driving high-margin biopharma partnerships and fueling its next-generation pipeline, including the Caris Detect multi-cancer early detection test. Trading at a discount relative to peers on an EV/Sales basis despite superior growth and improving profitability, CAI offers an attractive entry point for long-term investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$27.00

High · most bullish analyst$36.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Intense competition from well-funded rivals like Guardant Health and Tempus AI limits market share gains in liquid biopsy and MRD testing. Reimbursement pressures or delays in regulatory approvals slow down clinical adoption, causing revenue growth to fall below 15%. Heavy investments in clinical trials and commercial expansion continue to pressure net profitability, leading to cash burn and potential dilution.

Base CaseCentral scenario

The company successfully executes on its FY 2026 guidance of $1.0 billion to $1.02 billion in revenue, representing 23% to 26% growth. Clinical adoption of its core MI Profile and Caris Assure tests continues to expand across oncology networks. Gross margins remain stable at approximately 65-66%, and the company continues to generate positive free cash flow, supported by its $400 million term loan facility and $100 million share repurchase program.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Industry-leading molecular profiling platform with a massive clinico-genomic database of over one million cases.
Exceptional revenue growth (97% in FY 2025, 79% in Q1 2026) combined with strong gross margins of ~65-66%.
Transition to positive Adjusted EBITDA and positive free cash flow, reducing near-term financing risks.
Robust pipeline of AI-driven diagnostics, including Caris Detect and MI Clarity, targeting massive addressable markets.

Key Investment Risks

Intense competition in the precision oncology and molecular diagnostics market from established players.
Dependence on favorable reimbursement decisions from payers and regulatory approvals for new tests.
Near-term net income pressure due to high stock-based compensation and ongoing R&D/commercial investments.

Thesis Invalidation Triggers

A significant drop in molecular profiling case volumes or average selling prices (ASPs).
Failure to obtain key regulatory approvals or reimbursement coverage for Caris Assure and Caris Detect.
Reversion to substantial negative free cash flow and unsustainable cash burn rates.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.